The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity. by Becker, Jordan R et al.
ARTICLE
The ASCIZ-DYNLL1 axis promotes 53BP1-
dependent non-homologous end joining and PARP
inhibitor sensitivity
Jordan R. Becker1, Raquel Cuella-Martin1, Marco Barazas2, Rui Liu3, Catarina Oliveira 1, Antony W. Oliver 4,
Kirstin Bilham1, Abbey B. Holt5, Andrew N. Blackford6,7, Jörg Heierhorst 3,8, Jos Jonkers2,
Sven Rottenberg 2,9 & J. Ross Chapman 1
53BP1 controls a specialized non-homologous end joining (NHEJ) pathway that is essential
for adaptive immunity, yet oncogenic in BRCA1 mutant cancers. Intra-chromosomal DNA
double-strand break (DSB) joining events during immunoglobulin class switch recombination
(CSR) require 53BP1. However, in BRCA1 mutant cells, 53BP1 blocks homologous recombi-
nation (HR) and promotes toxic NHEJ, resulting in genomic instability. Here, we identify the
protein dimerization hub—DYNLL1—as an organizer of multimeric 53BP1 complexes. DYNLL1
binding stimulates 53BP1 oligomerization, and promotes 53BP1’s recruitment to, and inter-
action with, DSB-associated chromatin. Consequently, DYNLL1 regulates 53BP1-dependent
NHEJ: CSR is compromised upon deletion of Dynll1 or its transcriptional regulator Asciz, or
by mutation of DYNLL1 binding motifs in 53BP1; furthermore, Brca1 mutant cells and tumours
are rendered resistant to poly-ADP ribose polymerase (PARP) inhibitor treatments upon
deletion of Dynll1 or Asciz. Thus, our results reveal a mechanism that regulates 53BP1-
dependent NHEJ and the therapeutic response of BRCA1-deﬁcient cancers.
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To counteract the potentially carcinogenic effects of DNAdamage and mutation, cells employ a complex network ofDNA repair pathways1. DNA double-strand breaks (DSBs)
are among the most toxic of genomic lesions. They arise from a
variety of endogenous and exogenous sources, including ionizing
radiation (IR) treatments, replication fork collapse, and as pro-
grammed intermediates of antigen receptor gene rearrangements
during variable, diversity and joining (V(D)J) recombination and
class-switch recombination (CSR)2,3. DSBs are predominantly
repaired by homologous recombination (HR) and non-
homologous end joining (NHEJ) pathways. HR is an essential
DNA repair pathway owing to its utility in the repair of DSBs
encountered during the S/G2-phases of proliferating cell popu-
lations4, and mutations affecting its ﬁdelity are associated with
tumourigenesis1. HR initiation involves the regulated nucleolytic
resection of DSB termini in a 5ʹ–3ʹ direction, which is an
important determinant of whether a given break is repaired by
HR or NHEJ5. The resulting 3ʹ-tailed ends are used to invade
homologous sequences on the sister chromatid, which is used as a
template for accurate repair. The availability of a sister chromatid
in only replicated regions of the genome ensures that HR repair is
largely restricted to S and G2 phase cells, while NHEJ pre-
dominates in G13. NHEJ instead involves the direct ligation of
DSB ends, a mechanism utilized by developing and antigen-
stimulated lymphocytes to generate programmed deletions during
the diversiﬁcation of antigen receptor genes. However, inap-
propriate activity of the NHEJ pathway is also known to promote
genomic rearrangements and translocations associated with the
onset of cancer. Activation of the appropriate pathway for a given
DSB type, cellular context, or genomic locus is therefore crucial
for the maintenance of genome stability and avoidance of dele-
terious errors or mutations5.
TP53-binding protein 1 (53BP1) is a DSB responsive protein
that mediates an important and specialised branch of the NHEJ
pathway6. 53BP1 is rapidly recruited to DSB sites, where its
interaction with modiﬁed nucleosomes in DSB-ﬂanking chro-
matin functions to inhibit nucleolytic DNA end resection,
favouring DNA joining by NHEJ. This involves binding to a
combinatorial chromatin signature consisting of methylated his-
tone H4 (H4K20me1/2) and ubiquitinated H2A (H2AK15Ub)
within DSB-associated chromatin domains7,8, and the recruit-
ment of downstream effector proteins such as RIF1 (RAP1
interacting factor 1), whose binding to 53BP1 is required for
efﬁcient DNA end-protection and NHEJ9–11. RIF1-53BP1 com-
plexes are essential for immunoglobulin (Ig) CSR, an NHEJ-
driven deletional recombination reaction in activated B cells that
mediates the replacement of excised default IgM-encoding con-
stant (C) gene segments of the Ig heavy locus (Igh), with down-
stream C segments of different class and function (e.g., IgG, IgE
and IgA). Mice deﬁcient in 53BP1 or RIF1 are immunodeﬁcient
owing to CSR failure9,12–14, defects that manifest as a result of the
aberrant hyper-resection of Igh DSBs that generate ssDNA
intermediates non-amenable to NHEJ9,14,15. The 53BP1 pathway
also plays an equivalent but pathological role in DNA end-joining
at de-protected telomeres: telomeric DNA ends exposed upon
disruption of the telomere capping complex Shelterin are pre-
dominantly repaired by 53BP1-dependent NHEJ, resulting in
chromosome end fusions16. Accordingly, uncapped telomeric
DNA ends are hyper-resected in 53bp1- and Rif1-deﬁcient cells,
resulting in a near complete suppression of telomere end-
joining11,17.
53BP1-dependent NHEJ is also problematic in BRCA1-deﬁ-
cient cancers, where it mediates chromosomal rearrangements
that drive oncogenesis18,19. In mice, germline 53bp1-deletion
suppresses the embryonic lethality and mammary tumourigenesis
associated with homozygous Brca1 loss-of-function mutations, a
rescue explained by reactivation of HR19. Conversely, 53BP1
pathway-associated DSB repair activities underlie the synthetic
lethal effect of poly-ADP ribose polymerase (PARP) inhibitor
(PARPi) treatments in BRCA1 mutation-associated cancers:
genetic ablation of 53BP1 pathway components results in
PARPi resistance in cellular and tumour models of BRCA1-
deﬁciency9,20,21.
Aside from DSB repair, distinct 53BP1 protein complexes
regulate the activation of p53-dependent senescence programs
triggered in response to p53-activating drug treatments and
prolonged mitotic transit22–25. Here, 53BP1’s C-terminal BRCT
domains bridge p53’s interaction with the deubiquitinating
enzyme USP28, catalysing de-ubiquitination events that stimulate
p53 binding to, and activation of, target gene promoters22.
While mechanistically distinct, both NHEJ and p53-regulatory
functions require 53BP1 multimerization22,26,27, a function
thought to rely entirely on its oligomerization domain (OD;
encoded within amino acid residues (a.a.) 1231–1277)28. NHEJ-
deﬁcits have been attributed to an inability to recruit 53BP1 to
DSB-associated chromatin, as OD mutation/deletion blocks the
retention of 53BP1 protein fragments at DNA damage sites, and
also compromises their interaction with modiﬁed nucleosome
core particles in vitro8,28,29. Perhaps unexpectedly, we and others
recently reported that the recruitment of a full-length 53BP1
protein into IR induced foci (IRIF) was only modestly impacted
by OD- deletion or mutation22,27. This prompted us to explore
the molecular basis and function of OD-independent 53BP1
recruitment.
Here, we reveal that 53BP1 can interact with DNA damage
sites independently of its OD, and this recruitment depends on
interaction with the multifunctional homodimeric protein hub
dynein light chain 1 (DYNLL1). We demonstrate that DYNLL1
binding promotes ordered 53BP1 oligomerization and is
essential for efﬁcient CSR and adaptive immunity in mice,
while also contributing to 53BP1-dependent p53 regulation. In
addition, we show DYNLL1-53BP1 interplay plays an essential
role in mediating toxic NHEJ events in Brca1 mutant cancer
cells: deletion of DYNLL1 or its transcriptional regulator ATM
substrate Chk2-interacting Zn2+ ﬁnger protein (ASCIZ; also
known as ATMIN/ZNF822) is strongly selected for in BRCA1-
deﬁcient tumour cells, and results in PARPi resistance in vitro
and in vivo. Thus, our ﬁndings identify an important mechanism
in which DYNLL1 directly regulates the ﬁdelity of 53BP1-
dependent NHEJ.
Results
DYNLL1 is essential for OD-independent 53BP1 recruitment.
The minimal domain requirements for 53BP1 DSB localization
were deﬁned in the context of a 53BP1 fragment encompassing a.
a. 1220–171130,31. This fragment spans 53BP1’s nuclear locali-
zation sequence (NLS), OD, tandem-tudor, and ubiquitin-
dependent recruitment (UDR) domains, all of which were
essential for its recruitment into IRIF8,28. We were therefore
surprised that complete deletion of its OD domain (53BP1ODΔ)
or Ala mutation of four key residues for OD activity (53BP1ODm)
only negligibly impacted on 53BP1 IRIF frequencies, despite
completely blocking recruitment in the context of truncated
53BP11220–1711 proteins (Fig. 1a). To map the sequences in 53BP1
that mediate OD-independent recruitment, IRIF localization
patterns were examined across a panel of truncated 53BP1ODm
proteins in which 53BP1 sequences N- and C-terminal to a.a.
1220–1711 were restored (Fig. 1b and Supplementary Fig. 1a). We
found that the addition of 113 residues N-terminal to
53BP11220–1711 rescued 53BP1ODm recruitment into IRIF
(Fig. 1b), implicating a.a. 1107–1219 in OD-independent 53BP1
recruitment.
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Interestingly, alanine substitutions at 28 N-terminal [Ser/Thr]-
Gln consensus ATM/ATR phosphorylation site motifs in the full-
length 53BP1ODm protein recapitulated the effect of a.a.
1107–1219 deletion on IRIF recruitment (Fig. 1b), and suggested
that some of these Ser-Gln or Thr-Gln motifs may be involved in
the OD-independent 53BP1 recruitment to DSBs. We noted that
Thr-1171, one of the three Ser-Gln/Thr-Gln motifs in the region
critical for OD-independent IRIF formation (a.a. 1107–1219),
also serves as a binding site (consensus Thr-Gln-Thr) for the
dynein light chain protein DYNLL1 (LC8)32. As DYNLL1 is
known to function as a ubiquitous sequence-speciﬁc dimerization
hub for a plethora of diverse proteins33,34, we considered a role
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Fig. 1 DYNLL1 promotes OD-independent 53BP1 recruitment to DSB sites. a 53BP1-/- MCF-7 cells stably expressing the indicated 53BP1 transgenes were
irradiated (5 Gy), ﬁxed 4 h later, and immunostained with anti-HA (53BP1) and anti-γH2AX antibodies. Data, representative of n= 3 independent
experiments. ODΔ indicates deletion of amino acids 1230–1270 and ODm indicates mutation of amino acids 1258–1261 to alanine. b IRIF forming capability
of indicated 53BP1 constructs was determined in stable cell lines as in (a) 4 h following 5 Gy irradiation in a minimum of n= 2 independent experiments.
c As in (a-b), but with indicated WT and mutant 53BP1 constructs. Data, representative of n= 2 independent experiments. Amino acids 1142–1181 of 53BP1
are depicted including 6 amino acids mutated to alanine in the LC8m allele. d Automated 53BP1 IRIF quantiﬁcation of data in (c). Each point represents
a single nucleus with n ≥ 65 nuclei scored per condition. Median is indicated. Data, representative of n= 2 independent experiments. e Left, quantiﬁcation
of 53BP1 IRIF 4 h after irradiation (5 Gy). Signiﬁcance determined by Mann–Whitney U Test. Right, immunoblot analysis of experimental cell lines. Each
point represents a single nucleus with n ≥ 131 nuclei scored per condition. Median is indicated. Data, representative of n= 2 independent experiments.
f FLAG-HA-53BP1 immuno-complexes were isolated from whole cell extracts prepared from untreated and irradiated (10 Gy, 1 h) HEK 293 T cultures, 48 h
following transfection with indicated control (GST) or 53BP1 expression plasmids. Representative data, n= 2 independent experiments
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for DYNLL1 in the OD-independent 53BP1 recruitment
mechanism. 53BP1 a.a. 1107–1219 also contains a second
DYNLL1-binding site32, and indeed, alanine substitution of the
three anchor residues (GIQ and TQT, respectively) in each of the
two DYNLL1-binding site motifs of 53BP1 (53BP1LC8m)
completely blocked OD-independent 53BP1 IRIF formation
(Fig. 1c–d). Moreover, we found that DYNLL1 colocalized with
53BP1 in nuclear foci and that this interaction was abolished by
the 53BP1LC8m mutations (Supplementary Fig. 1b). However, the
53BP1LC8m mutation did not interfere with OD-mediated
oligomerization in vitro (Supplementary Fig. 2a), or downstream
RIF1 recruitment (Supplementary Fig. 2b, c). Thus, collectively,
these data indicate that direct binding of DYNLL1 to the LC8-
binding motifs is critical for the OD-independent recruitment of
53BP1 to DSB sites.
To further explore DYNLL1’s role in modulating 53BP1
functions, we used CRISPR-Cas9 to mutagenize the DYNLL1
gene in 53BP1-/- MCF-7 cell populations stably complemented
with wild type (WT) 53BP1 or 53BP1ODm. DYNLL1-depletion in
these populations (without selection for stable DYNLL1 knockout
clones) caused a near complete block in 53BP1ODm foci
formation (Fig. 1e and Supplementary Fig. 2d, p < 0.0001), and
residual 53BP1 IRIF frequencies in these experiments correlated
to cells of increased DYNLL1 nuclear staining intensity
(Supplementary Fig. 2e). In contrast, DYNLL1-depletion did
not affect the frequencies of WT 53BP1 IRIF when the OD was
intact (Fig. 1e; p= 0.1363). These experiments therefore sug-
gested that DYNLL1-dependent binding to the LC8 motifs in
53BP1 promotes 53BP1 oligomerization, explaining the mechan-
ism of OD-independent 53BP1 recruitment to IRIFs.
DYNLL1-53BP1 interactions are DNA damage- and cell cycle-
independent. As indicated above, one of the two LC8 motifs (LC8
motif 2) in 53BP1 also comprises an ATM/ATR phosphorylation
site (Thr-1171, consensus Thr-Gln) that is phosphorylated fol-
lowing IR-treatment35, and a second putative ATM phosphor-
ylation site (Ser-1148) is positioned only 5 a.a. residues upstream
of LC8 motif 1. Thus, we considered that 53BP1-DYNLL1
interactions might be DNA damage regulated. To test this, Flag-
HA tagged WT 53BP1 and 53BP1LC8m mutant protein complexes
were immunoprecipitated from lysates prepared from irradiated
and untreated stable cell lines and analyzed for the presence of
DYNLL1. In conﬁrmation of a role for the 53BP1 LC8 motifs in
mediating DYNLL1 interactions, DYNLL1 co-precipitated with
wild type, but not LC8-motif mutant 53BP1 complexes (Fig. 1f).
Notably, DYNLL1-53BP1 interactions were not signiﬁcantly
altered upon IR-treatments (Fig. 1f), discounting a role for Thr-
1171 phosphorylation in regulating DYNLL1-53BP1 interactions.
In addition, mutation of Ser-1148, which would be expected to
form the N-terminal residue of the fully extended ~8-residue
beta-strand interacting with the DYNLL1-binding groove based
on known structures for DYNLL1-target complexes36, by itself
had only a modest effect on DYNLL1 binding. Mutation of Thr-
1171, however, reduced DYNLL1-binding to a greater extent,
which was further reduced in concert with the Ser-1148-Ala
mutation, albeit not to the same extent as the 53BP1LC8m
interaction-blocking mutation in which the entire 3-residue
anchor motifs are disabled (Supplementary Fig. 1c). Moreover,
combined alanine substitutions at Thr-1171 and Ser-1148 resul-
ted in the near total loss of OD-independent 53BP1 IRIF (Sup-
plementary Fig. 1d). The most likely explanation for these results
is that mutation of these two phosphorylation site motifs impacts
the interaction with DYNLL1 by weakening its binding sites in
53BP1 rather than by impairing their phosphorylation state,
reconciling the IRIF recruitment defect of the 53BP1ODm,28A
mutant protein (Fig. 1b).
Next, we examined whether DYNLL1-53BP1 interactions
might be regulated by cell cycle position. Cell synchronisation
experiments conﬁrmed DYNLL1 did not exhibit cell-cycle-
dependent ﬂuctuations in expression during interphase (Supple-
mentary Fig. 3a), or mitosis (Supplementary Fig. 3b). To
determine whether 53BP1 might be regulated by cell-cycle
dependent modiﬁcation of DYNLL1, or otherwise, 53BP1 IRIF
were quantiﬁed in G1, S and G2 cell-cycle stage classiﬁed
populations in WT and mutant complemented 53BP1-/- MCF-7
stable cell lines (Supplementary Fig. 3c). Here, the 53BP1LC8m
mutation did not signiﬁcantly impair foci formation at any cell
cycle phase (Supplementary Fig. 3d). Likewise, 53BP1ODm IRIF
frequencies, that rely entirely on DYNLL1-interactions (see
Fig. 1c–f), were equally reduced at all cell cycle phases
(Supplementary Fig. 3d). Collectively, these experiments indicate
DYNLL1-53BP1 interactions are likely to be constitutive, and
suggested that DYNLL1 might represent an integral component
of 53BP1 complexes.
53BP1-DYNLL1 interactions are required for class-switch
recombination. We next examined the function of DYNLL1
and DYNLL1-53BP1 interactions during CSR, which relies on
53BP1-mediated NHEJ12,13. DYNLL1 is essential for normal B
cell development, and its deletion in the early B cell lineage using
Mb1-Cre leads to dramatic losses in circulating and mature
splenic B cell populations (Supplementary Fig. 4a)37. We there-
fore used transgenic Cd23-Cre driver (Cd23-CreTg) to delete
Dynll1 in mature B lymphocytes in Dynll1F/F mice, which sup-
ported the development of normal frequencies of mature splenic
B cells in which DYNLL1 protein was efﬁciently depleted (Sup-
plementary Fig. 4b, c). Cultured Dynll1-deleted B splenocytes
upon stimulation with IL-4 and LPS showed a reduction in class-
switching to IgG1, and IgG1 switching frequencies in Cd23-CreTg
Dynll1F/F cells were consistently reduced by >50% relative to
Cd23-CreTg controls in all cell populations that had undergone
equivalent numbers of cell divisions (Fig. 2a, b). This was inde-
pendently conﬁrmed by Cd23-Cre-mediated deletion of the Asciz
gene in mouse mature B cells, which encodes DYNLL1’s tran-
scriptional regulator ASCIZ (ATMIN)38,39 and resulted in greatly
reduced DYNLL1 expression and an equivalent reduction in
class-switching efﬁciency (Supplementary Fig. 4d, e), consistent
with previous results in B cells from Cd19-Cre Asciz-mutant
mice40. The fact that CSR defects in Dynll1- and Asciz-deleted B
cells could not be explained by the defective expression of Igh
switch region germ-line transcripts (Supplementary Fig. 4f), nor
the magnitude of proliferation defects in Dynll1-deleted B cells
(Fig. 2b), was consistent with a role for DYNLL1 and its regulator
ASCIZ in the end joining phase of CSR.
To exclude the possibility that indirect, 53BP1-independent,
consequences of DYNLL1-deletion could account for CSR defects
in Dynll1-deﬁcient B cells, we next monitored the effect of LC8
binding site mutations on 53BP1-dependent CSR. LPS/IL-4-
induced class-switching to IgG1 was analysed in stimulated
53bp1-/- primary B splenocytes upon reconstitution with retro-
viruses that express wild type 53BP1, or the 53BP1ODm,
53BP1LC8m, and 53BP1LC8m/ODm mutant proteins, or as a
negative control, the NHEJ-defective 53BP1L1619A UDR mutant8
(Fig. 2c; note that to avoid the inefﬁcient packaging of large
53BP1 inserts in retroviral particles, all rescue constructs express a
truncated 53BP1 protein (a.a. 1–1711) that supports WT CSR
frequencies26). As expected, 53BP11–1711 expression rescued class
switching in 53bp1-/- B cell cultures, while the repair-deﬁcient
53BP1L1619A mutant could not (Fig. 2c, d). In contrast,
53BP1LC8m-reconstitution only restored CSR to ~50% of WT
(Fig. 2c, d), a defect consistent in magnitude to Dynll1-deﬁcient B
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cells, conﬁrming DYNLL1 mediates CSR via its regulation of
53BP1 complexes and their NHEJ activities. As expected26,
53bp1-/- B cells complemented with a mutant OD-domain allele
(53BP1ODm) failed to restore CSR to any signiﬁcant degree
(Fig. 2c, d). Thus, while DYNLL1 can mediate OD-independent
53BP1 DSB recruitment, OD-independent recruitment alone is
unable to support NHEJ during CSR, conﬁrming a cooperation
between OD- and DYNLL1-dependent oligomerization in the
assembly of NHEJ-competent 53BP1 oligomers.
DYNLL1 stimulates 53BP1 oligomerization to promote opti-
mal chromatin interactions. To ascertain why DYNLL1-
mediated 53BP1 recruitment alone is insufﬁcient for DNA
repair, we investigated DYNLL1’s contribution to 53BP1-
chromatin interaction dynamics at DSB sites. Stable 53BP1-/-
MCF-7 cell lines were established that expressed equivalent levels
of an mC2 (mClover2)-tagged 53BP1 a.a. 1107–1711 fragment,
comprising WT (mC2-f53BP1) or mutated versions of the OD
(mC2-f53BP1ODm) or LC8 motifs (mC2-f53BP1LC8m). The
mobility of each protein in IRIF was then calculated in ﬂuorescent
recovery after photobleaching (FRAP) experiments (Fig. 3a).
Fluorescence recovery of mC2-f53BP1ODm was >3-fold faster
than that of WT mC2-f53BP1 protein, as calculated from the
half-time for recovery to maximum ﬂuorescence: t1/2= 47.3 s ±
18.12 and 163.25 s ± 46.9, for mC2-f53BP1ODm and mC2-f53BP1
proteins, respectively (Fig. 3b, c). Thus, DYNLL1-mediated
53BP1 oligomerization alone is insufﬁcient for stable chromatin
interaction at DSB sites. These results conﬁrm canonical
DYNLL1-independent oligomerization is primarily responsible
for 53BP1 interactions with DSB-associated chromatin. To con-
trol for variation in ﬂuorescence recovery endpoints between
experimental repeats (Fig. 3d), we analyzed the rate of ﬂuores-
cence recovery in a manner that, unlike t1/2, was not related to the
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endpoint. Thus, we computationally modelled the ﬂuorescence
recovery data of three independent experiments (each comprising
n > 8 cells per genotype) to calculate the initial rate of ﬂuores-
cence recovery immediately after photobleaching (Fig. 3d). Initial
rate calculations provide a concentration-independent measure-
ment of ﬂuorescence recovery that is independent of ﬂuorescence
recovery endpoint. Consistent with t1/2 measurements, the initial
recovery rates of each protein reproduced the trends seen in
Fig. 3b, c, with large, and moderate increases in the recovery rates
of mC2-f53BP1ODm and mC2-f53BP1LC8m mutant proteins,
respectively, relative to WT mC2-f53BP1 (Fig. 3e). These data
conﬁrmed an important role for DYNLL1 in stabilizing OD-
dependent 53BP1-chromatin interactions.
To determine the mechanism by which DYNLL1 contributes to
53BP1 function, we next probed DYNLL1’s ability to promote
53BP1 oligomerization in vitro. Thus, puriﬁed DYNLL1 was
titrated into binding reactions that contained a recombinant
monomeric 53BP1 protein fragment encoding the two LC8-
binding motifs and a mutated OD domain (a.a. 1131–1292).
Reactions were then resolved by native PAGE to ascertain
DYNLL1’s ability to stimulate OD-independent 53BP1 oligomer-
ization. In these experiments, increasing DYNLL1 to levels
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equimolar and above that of the 53BP1 fragment, stimulated its
robust oligomerization as determined by a marked increase in
higher molecular weight protein complexes (Fig. 3f). In
conﬁrmation of a role for the 53BP1 LC8 binding motifs in
mediating the assembly of DYNLL1-bridged 53BP1 oligomers,
higher molecular weight complexes did not form when both LC8-
binding motifs in the 53BP1 fragment were mutated, and
these reactions were characterised by an increased presence of
ligand-free DYNLL1 dimers (Fig. 3f). Taken together, our data
indicate that optimal 53BP1 oligomerization is mediated via a
cooperation between its OD-domain (Fig. 1a, b), and the
binding of DYNLL1 to its upstream binding sites in 53BP1
(Fig. 3f). We therefore conclude that the intermolecular
afﬁnity afforded by DYNLL1-53BP1 interactions is sufﬁcient to
promote 53BP1 oligomerization, yet in isolation is insufﬁcient
to efﬁciently tether 53BP1 complexes to DSB-associated chroma-
tin. We instead propose that DYNLL1 may provide order to
large oligomeric 53BP1 complexes, a function required for
optimal chromatin interactions and its associated DNA repair
function.
PARPi hypersensitivity in Brca1-deﬁcient cells requires 53BP1-
DYNLL1 cooperation. The fact that DYNLL1-mediated regula-
tion of 53BP1 oligomerization enhances 53BP1-dependent CSR
next prompted us to test its importance more broadly in 53BP1-
dependent NHEJ. The efﬁcacy of PARPi in killing BRCA1-deﬁ-
cient cells is dependent on 53BP1, and its loss in BRCA1-deﬁcient
cell-lines and mice results in resistance to PARPi-induced cell
death9,19–21. We therefore theorized that reduced efﬁciency of
53BP1-dependent NHEJ upon DYNLL1 depletion might likewise
confer PARPi resistance to BRCA1-deﬁcient cells. Using CRISPR-
Cas9, we mutagenized the Dynll1 and Asciz genes in the KB1P-G3
Brca1-/- p53-/- murine mammary tumour cell line20, and mon-
itored locus-speciﬁc indels within cell populations by deconvo-
lution of complex Sanger sequencing traces derived from Cas9
cleavage site-spanning PCR amplicons using the Tracking of
Indels by Decomposition (TIDE) algorithm41 (Supplementary
Fig. 5a). To determine whether mutation of Dynll1 or Asciz
provided a selective advantage in KB1P-G3 cells due to PARPi
resistance, the change in percentage of edited alleles between
the starting population and the surviving fraction was
compared, before, and after, outgrowth in the presence or
absence of the PARPi olaparib (Fig. 4a and Supplementary
Fig. 5a). In all experiments in which the initial indel frequency at
the Dynll1 and Asciz loci was below saturation (<85%) in treat-
ment naive cells, olaparib treatments selected for striking
increases in indel frequency (Fig. 4b and Supplementary Fig. 5b).
These effects were coupled to reductions in DYNLL1 protein
levels when compared to untreated controls (Supplementary
Fig. 5c), collectively conﬁrming that both proteins are required
for the hypersensitivity of Brca1-deﬁcient cells to PARPi. Cas9-
dependent mutagenesis of either gene in KB1P-G3 cells also
conferred olaparib resistance in clonogenic survival experiments
(Fig. 4c, d). Importantly, the Olaparib resistance in Asciz-mutated
KB1P-G3 cells could be completely reversed by transgene-
mediated re-expression of exogenous DYNLL1 (Supplementary
Fig. 6a–c), conﬁrming the importance of ASCIZ-mediated
DYNLL1 transcription in the response of BRCA1-deﬁcient cells
to PARPi. However, neither selection for CRISPR-Cas9-
dependent Dynll1 or Asciz locus editing, nor reduced DYNLL1
expression, was observed when equivalent experiments per-
formed in 53bp1-/- KB1P-G3 cells (Fig. 4e and Supplementary
Fig. 5d, e), indicating that DYNLL1’s role in mediating the PARPi
sensitivity of Brca1-deﬁcient cells occurs predominantly via its
regulation of 53BP1 activities.
We next examined whether the ASCIZ-DYNLL1 axis was
required for PARPi sensitivity in vivo. ASCIZ and DYNLL1 have
previously been shown to have equivalent effects on the
development and expansion of Myc-driven cancers37,42, thus we
monitored the growth of Cas9-expressing Brca1-/- p53-/- trans-
planted mouse cancer organoids43 transduced with control or
Asciz-targeting gRNA (Supplementary Fig. 5f, g). Olaparib
treatment signiﬁcantly delayed the onset of tumour growth in
transplanted animals relative to an untreated cohort. However,
PARPi-dependent inhibition of tumour growth was attenuated in
Asciz-edited tumours (Fig. 4f), and resulted in decreased overall
survival relative to control olaparib-treated cohorts (Fig. 4g).
These data demonstrated that regulation of 53BP1 by the ASCIZ-
DYNLL1 axis supports the efﬁcacy of olaparib treatments in
selectively killing Brca1-deﬁcient cancer cells, conﬁrming the
importance of DYNLL1-53BP1 interactions in regulating 53BP1-
dependent DNA repair.
DYNLL1-binding sites contribute to 53BP1-dependent Nutlin-
3 sensitivity. In addition to its role in the DNA damage response,
53BP1 also contributes to p53-dependent transcriptional senes-
cence programs and the corresponding cellular sensitivity to the
treatments with MDM2 inhibitor Nutlin-322,44. Interestingly, the
53BP1LC8m mutant, in contrast to wild type 53BP122, was com-
promised in their ability to restore the sensitivity of 53BP1-/-
MCF-7 to Nutlin-3 (Fig. 5a–c). This agrees with a model in which
DYNLL1 is likely to enforce optimal 53BP1 oligomerization, and
is consistent with our published ﬁndings in which efﬁcient 53BP1
oligomerization was similarly essential for 53BP1-dependent
regulation of p5322.
Discussion
Taken together, our ﬁndings reveal DYNLL1 to be an integral
component of oligomeric 53BP1 complexes through which it
plays an important role in 53BP1-dependent NHEJ. We speculate
that DYNLL1-binding to 53BP1 may provide order to 53BP1
oligomers within chromatin-binding domains, enhancing pro-
ductive chromatin interactions that enhance effective resection
inhibition and enable for efﬁcient NHEJ. Deﬁciencies in either
DYNLL1 or its binding sites in 53BP1, lead to substantial CSR
defects. Given that 53BP1 is similarly important for resection
inhibition and NHEJ during V(D)J recombination, a loss of
which manifests in the defective development of B and T lym-
phocyte lineages45–47, it is plausible that 53BP1-associated V(D)J
recombination defects that accompany loss of DYNLL1-53BP1
interactions might contribute to the B cell lineage development
defects recently reported in Dynll1-deﬁcient mice37. We also
found that DYNLL1 contributes to DNA damage-independent
53BP1 functions in the response to the MDM2 inhibitor Nutlin-3
(Fig. 5a–c). This agrees with a model in which DYNLL1 enforces
optimal 53BP1 oligomerization, and is consistent with our pub-
lished ﬁndings in which efﬁcient 53BP1 oligomerization was
similarly essential for 53BP1-dependent regulation of p5322. Our
results therefore suggest bivalent oligomerization modes are
necessary to coordinate the assembly of 53BP1 molecules into
ordered, functionally competent multimeric complexes, insights
that will be relevant for understanding other macromolecular
complexes organized by DYNLL1 (Fig. 6). In identifying DYNLL1
and ASCIZ as essential mediators of 53BP1-dependent PARPi
sensitivity in Brca1-deﬁcient cancer cells, our ﬁndings provide a
molecular explanation for the identiﬁcation of both proteins as
PARPi resistance factors in BRCA1-deﬁcient cells in recently
published genetic screens48,49, and reveal a previously unantici-
pated mechanism in which 53BP1 misregulation could lead to
PARPi resistance in the clinic.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07855-x ARTICLE
NATURE COMMUNICATIONS |          (2018) 9:5406 | https://doi.org/10.1038/s41467-018-07855-x | www.nature.com/naturecommunications 7
Methods
Cell lines and culture conditions. Cell lines used in this study are MCF-7 female
human breast adenocarcinoma, RPE-1 female human retinal pigment epithelial,
human female embryonic kidney (HEK) 293T cells (including the BOSC23 deri-
vative cell line), and KB1P-G3 Brca1-/- p53-/- cells which were isolated from a
female mouse mammary tumour. All cell lines were checked for mycoplasma
contamination. KB1P-G3 and the KB1P-G3 53bp1-/- derivative were both kindly
provided by Sven Rottenberg (NKI, Netherlands and University of Bern). All cell
lines were cultured in DMEM—high glucose (D6546, Sigma-Aldrich) supple-
mented with 10% FBS, Pen-Strep, and 2 mM L-glutamine. Cultures were grown
at 37 °C with 5% CO2. KB1-P3 (G3) and all derivative cells lines were additionally
grown in 3% oxygen. Primary B cells were isolated from red blood cell-lysed
single-cell suspensions of 53bp1-/- C57BL/6J mouse spleens and cultured in
RPMI supplemented with 10% FCS, 100 U/ml penicillin, 100 ng/ml streptomycin,
2 mM L-glutamine, 1x MEM nonessential amino acids, 1 mM sodium pyruvate
and 50 μM β-mercaptoethanol.
Mouse models. Mice harbouring conditional Dynll1 or Asciz alleles (MGI ID:
5755433 and 5463697, respectively) were intercrossed with Cd23-Cre transgenic
mice (MGI ID: 3803652) to generate Cd23-CreTg Dynll1F/F and Cd23-CreTg AscizF/F
experimental and Cd23-CreTg control animals. Mouse breeding and tissue
collection was performed according to the Australian Code for the Care and
Use of Animals for Scientiﬁc Purposes, 8th Edition (2013), and approved by the
St. Vincent’s Hospital Melbourne Animal Ethics Committee, approval number
002/17. 53bp1-/- C57BL/6J mouse breeding and tissue collection was carried out
according to the Animals (Scientiﬁc Procedures) Act (ASPA) under a Home Ofﬁce
project license to JRC.
Gene editing and complementation. CRISPR-Cas9 editing was carried out with
gene-speciﬁc gRNAs integrated into a version of lentiCRISPR v2 (Addgene #52961)
modiﬁed for blasticidin (lentiCRISPR-Bsr) resistance. Lentivirus was generated by
co-transfection of lentiCRISPR-Bsr, pHDM-tat1b, pHDM-G, pRC/CMV-rev1b,
and pHDM-Hgpm2 into HEK 293T cells using 1.29 μg polyethylenimine per 1 μg
DNA in Opti-MEM (Thermo Fisher, 31985062). Viral supernatants were harvested
at 48 and 72 h and passed through a 0.45-μm syringe ﬁlter. Two rounds of viral
transduction were carried out on target cell populations in the presence of 4 μg/ml
polybrene before selection in 10 μg/ml blasticidin. Once all cells in a non-
transduced control population had died, the CRISPR population was removed
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from blasticidin selection. Stable transgene expression was similarly achieved by
two rounds of lentiviral transduction with viral supernatants generated using the
same procedure.
Immunoﬂuorescence. For analysis of ﬁxed samples, cells were seeded (1.5 × 105)
on glass coverslips (13 mm) in six-well plates 2 days before irradiation. IRIF for-
mation was induced with γ-irradiation (5 Gy) and cells were ﬁxed in 2% paraf-
ormaldehyde after 4 h recovery. Fixed cells were rinsed with PBS and then
permeabilized in a 0.2% Triton X-100 PBS solution. After 15 min of blocking (3%
BSA, 0.1% Triton X-100 in PBS) coverslips were incubated 1 h in a humidity
chamber with primary antibodies diluted in blocking solution. The following pri-
mary antibodies were utilized at the indicated concentrations: mouse anti-HA
(1:200, HA.11 Biolegend), rabbit anti-γ-H2AX (1:500, Epitomics), rabbit anti-
Cyclin A (1:200, Santa Cruz sc-751), rabbit anti-DYNLL1 (1:250, AbCam
Ab51603). The coverslips were rinsed three times with PBS containing 0.1% TX-
100 and then incubated 1 h in a humidity chamber with secondary antibody. The
following secondary antibodies were utilized at the indicated concentrations: goat
anti-mouse Alexa Fluor 488 (1:500, Invitrogen A-11001), goat anti-rabbit Alexa
Fluor 568 (1:500, Invitrogen A-11011). Coverslips were then washed three times in
PBS containing 0.1% TX-100, once in PBS, and mounted on glass microscope slides
using ProLong® Gold antifade reagent with DAPI (Life Technologies, P36935).
In experiments involving EdU incorporation, cultures were pulsed with 40 μM
EdU for 10 min immediately preceding irradiation. After ﬁxation, EdU was labelled
using the Click-iT™ EdU Alexa Fluor 647 Imaging Kit (Thermo Fisher, C10340)
according to the manufacturer’s protocol. This was done immediately prior to
antibody staining as described above.
Images for the initial mapping of the LC8 domain within the 53BP1 N-terminus
(Fig. 1) were acquired on a Zeiss LSM510 META confocal imaging system (Fig. 1).
RIF1 IRIF (Supplementary Fig. 2b, 2c) were analyzed on a Leica SP8 SMD X
confocal microscope. All other ﬁxed IRIF images were acquired on an Olympus
Epi-ﬂuorescence MMI CellEctor wideﬁeld microscope. Quantitative analysis of
IRIF number and staining intensity was performed using Cell Proﬁler (Broad
Institute). All image visualization and processing was done using Fiji.
Olaparib sensitivity assays. KB1P-G3 and KB1P-G3 53bp1-/- cells were subjected
to two rounds of lentiviral transduction with viral supernatant generated using
lentiCRISPR-Bsr. After selection in blasticidin (10 μg/ml), samples were collected
to isolate genomic DNA (gDNA) immediately prior to seeding for olaparib sen-
sitivity. Blasticidin-resistant populations were seeded in six-well plates at a density
of 104 cells per well (5 × 103 for the KB1P-G3 53bp1-/- derivative) in the presence of
olaparib or DMSO and grown at 37 °C (5% CO2 and 3% O2). Medium was
refreshed at 4 days and 8 days. After 10 days outgrowth, cultures were expanded in
fresh medium for 1 week in 6 cm dishes before harvesting gDNA. PCR fragments
encompassing the CRISPR cut site were ampliﬁed from gDNA using Q5 poly-
merase (NEB, M0491), sequenced (GATC Biotech), and analyzed by Tracking of
Indels by Decomposition (TIDE: https://tide.deskgen.com/). Surviving cells were
collected and three replicates were plated in DMSO and three in olaparib for
viability analysis. DMSO and olaparib-treated cells were stained with crystal violet
(0.5% (w/v) crystal violet in 25% methanol) after 8 days and 10 days growth (37 °C,
5% CO2 and 3% O2), respectively. Crystal violet stained cells were dissolved in a
10% (v/v) acetic acid solution a minimum of 24 h after staining and the OD595 was
measured as a quantitative metric of relative growth.
Nutlin-3 sensitivity assay. Cells were seeded in triplicate at a density of 1.25 × 104
per well in a six-well plate in the presence (11 days growth) or absence (7 days
growth) of Nutlin-3 (4 μM, Cayman Chemicals, added 16 h after seeding). Cells
were stained with crystal violet and quantiﬁed as described for olaparib sensitivity
assays. These experiments were performed in triplicate.
Protein extraction and western blotting. Protein extracts were prepared in ice
cold benzonase cell lysis buffer (40 mM NaCl, 25 mM Tris pH 8.0, 0.05% SDS,
2 mM MgCl2, 10 U/ml benzonase, and cOmplete™ protease inhibitor cocktail
(Roche, 04693159001). Brieﬂy, cells were harvested and washed once in ice cold
PBS before resuspending in lysis buffer. After 10 min incubation on ice, protein
concentration was calculated by Bradford (Bio-Rad, 500-0006) assay with reference
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to a standard curve generated with BSA. Extracts were mixed with 3X Laemmli
buffer and heated at 95 °C for 5 min.
Extracts were fractionated on pre-cast NuPAGE™ 4–12% 1.0 mm Bis-Tris
polyacrylamide gels (Life Technologies, NP0322) and transferred to nitrocellulose
membranes. After blocking with 5% milk and washing in PBST, membranes were
incubated overnight in primary antibody. Primary antibodies used in this study are:
anti-53BP1 (Novus Biological, NB100-304, 1:2500), anti-DYNLL1 (Abcam,
ab51603, 1:1000), anti-α-tubulin (Sigma-Aldrich, TAT-1, 1:10000), anti-Cyclin A
(Santa Cruz, sc53227, 1:1000), anti-HA (BioLegend, 501901, 1:2000), and anti-
RPA32 (Abcam, ab16855, 1:1000), anti-β-actin (Sigma-Aldrich, A1978, 1:2000).
Membranes were then probed with HRP-conjugated goat anti-mouse (Thermo
Fisher, 62-6520) or goat anti-rabbit (Thermo Fisher, 65-6120) secondary
antibodies for 1 h (1:20000). The membranes were then developed using Clarity™
Western ECL Substrate (Bio-Rad, 170-5061) and visualized on a Gel Doc™ XR
System (Bio-Rad).
Class switch recombination. B cells were puriﬁed from red blood cell-lysed single-
cell suspensions of 8–16-week-old 53bp1-/- C57BL/6 J mouse spleens by magnetic
negative selection using a B Cell Isolation Kit (Miltenyi Biotec, 130-090-862). No
controls were employed for gender and randomization methods were not used to
allocate animals to control and experimental groups. B cells (7.5 × 105 per well in a
six-well plate) were cultured in RPMI supplemented with 10% FCS, 100 U/ml
penicillin, 100 ng/ml streptomycin, 2 mM L-glutamine, 1x MEM nonessential
amino acids, 1 mM sodium pyruvate and 50 μM β-mercaptoethanol. B cells were
stimulated with 5 μg/ml LPS (Sigma, L7770-1MG) and 10 ng/ml mouse recombi-
nant IL-4 (Peprotech, 214-14-20). Cultures were grown at 37 °C with 5% CO2
under ambient oxygen conditions.
Retroviral supernatants were collected 48 h after co-transfection of BOSC23
cells with 7 μg pCL-Eco and 7 μg pMX-IRES-GFP-derived plasmids (both kindly
provided by A. Nussenzweig) containing cloned transgene inserts in the presence
of FuGENE 6 (Promega, E2691). Viral supernatants were passed through a 0.45 μm
syringe ﬁlter. One round of viral transduction was carried out on B cells 24 h after
stimulation in the presence of 2.5 μg/ml polybrene, 20 mM HEPES, 5 μg/ml LPS
and 10 ng/ml mouse recombinant IL-4. B cells underwent spinoculation at 850×g
for 90 min at 30 °C. After a rest period of 4 to 6 h, the viral supernatants were
removed, and supplemented RPMI was added to the cells.
Three days after transduction, infected B cells were analysed for the percentage
of GFP and IgG1 double-positive cells using a FACSCanto (Becton Dickinson);
analysis was performed using FlowJo v10. Cells were resuspended in PBS with 2%
BSA and 0.025% sodium azide, blocked with Mouse BD Fc Block™ (1:500, BD
Pharmingen 553141), and immunostained with biotinylated rat anti-mouse IgG1
(1:100, BD Pharmingen 553441), and Streptavidin APC (1:500, eBioscience 17-
4317-82). Live/dead cells were discriminated after staining with Zombie Aqua
viability dye (1:200, BioLegend 423102).
For CSR analyses of Cd23-CreTg Dynll1F/F and Cd23-CreTg AscizF/F mice,
experiments were performed as above except that puriﬁed B cells were activated
with 10 µg/ml LPS (Invivogen, tlrl-3pelps) and 1:100-diluted conditioned murine
IL-4 supernatant (kind gift of Andreas Strasser, Walter and Eliza Hall Institute,
Melbourne) for 4 days, and then stained with CellTrace Violet (Thermo Fisher
Scientiﬁc, C34557) and rat anti-mouse IgG1-APC (BD Pharmingen, 550874).
To analyse the transcription of Igh germline transcripts, 3 × 106 MACS-puriﬁed
B cells from Cd23-CreTg, Cd23-CreTg AscizF/F, or Cd23-CreTg Dynll1F/F mice were
cultured with LPS (15 µg/mL) and IL-4 (1/100) for 0 to 3 days. After treatment,
cells were washed once with ice-cold PBS and cell pellets were snap frozen on dry
ice and stored at −80 °C before RNA extraction. Total RNA was extracted by using
ISOLATE II RNA Micro Kit (Bioline BIO-52075) following the manufacturer’s
protocol. 300 ng puriﬁed RNA was subjected to reverse transcription with oligo
(dT) and random primers using the SuperScript® III First-Strand Synthesis System
(Invitrogen™ 18080-051). qPCR reagents were mixed as follows: 4 µl cDNA (6 ng),
0.5 µl Primer mix (300 nM each), 5 µl SYBR™ Select Master Mix (Applied
Biosystems™ 4472908), 0.5 µl RNAase/DNAase free water. qPCR conditions were
set as follows: 1 cycle (10 min at 95 °C), 45 cycles (15 s at 95 °C), 60 s at 60 °C.
After each PCR run, a disassociation curve program was added to validate the
primer speciﬁcity. The standard curve method of comparative quantiﬁcation was
employed to quantify the results50. Results for the Iγ1-Cγ1 germline transcript were
normalized to the Cd79b input control, and expressed as percentage of maximum
expression. Primer sequences were the same as previously used51: Cd79b_forward
(5ʹ-TGTTGGAATCTGCAAATGGA-3ʹ), Cd79b_reverse (5ʹ-TAGGCTTT
GGGTGATCCTTG-3ʹ), Iγ1-Cγ1_forw (5ʹ-TCGAGAAGCCTGAGGAATGTG-3ʹ),
Iγ1-Cγ1_rev (5ʹ-GGATCCAGAGTTCCAGGTCACT-3ʹ).
Immunoprecipitation. One day before transfection, 4.5 × 106 HEK 293T cells
were seeded in antibiotic-free DMEM in a 10 cm plate for each condition. 24 h
after plating, cultures were transfected with 10 μg 53BP1 pLV-EF1α-FLAG-HA
Puro or 53BP1LC8m pLV-EF1α-FLAG-HA Puro using polyethylenimine. 24 h
after transfection, each culture was trypsinized and re-plated in 2 × 10 cm plates.
After 24 h, one plate was X-ray irradiated (10 Gy) and both (irradiated and non-
irradiated control) were harvested 1 h after irradiation. Cells were lysed in
benzonase-containing lysis buffer (20 mM HEPES [pH 7.9], 40 mM KCl, 2 mM
MgCl2, 10% glycerol, 0.5% NP40, 0.05% [v/v] phosphatase inhibitor cocktails 2
and 3 (Sigma-Aldrich), 1X protease inhibitor (Roche), and benzonase [50 U/ml])
on ice for 10 min. KCl was adjusted to a ﬁnal concentration of 450 mM and
rotated at 4 °C for 30 min before clariﬁcation. Clariﬁed lysates were diluted to a
ﬁnal salt concentration of 150 mM KCl with No-salt equilibration buffer (20 mM
HEPES [pH 7.9], 0.5 mM DTT, 0.05% [v/v] phosphatase inhibitor cocktails 2 and 3
(Sigma-Aldrich), 1X protease inhibitor (Roche)) and 2 mg of protein was
incubated with anti-FLAG M2 magnetic beads for 2 h. Bead-substrate
complexes were washed ﬁve times in wash buffer (20 mM HEPES [pH 7.9],
100 mM KCl, 0.5 mM DTT, 1X protease inhibitor (Roche)) at 4 °C before elution
with 3x FLAG peptide (150 mM NaCl, 0.05% Tween, 150 ng/μl FLAG peptide
(Sigma-Aldrich)). Eluates were boiled with Laemmli buffer and fractionated by
SDS-PAGE.
FRAP. 53BP1-/- MCF-7 cells were stably transduced with an mClover2-tagged
fragment of 53BP1 encompassing amino acids 1107–1711 of the wild type protein.
Two days before FRAP, 2.5 × 105 cells were seeded on a 35 mm glass-bottom plate.
Cells were irradiated (5 Gy) with an X-ray source to induce IRIF formation 2 h
before imaging. Individual foci were selected and 10 prebleach images were
acquired prior to a single bleach pulse with an Argon laser at a laser transmission of
100%. Immediately after bleaching, 120 images were acquired in 5 s intervals at
0.5% laser intensity. All acquisition ﬁles were processed in ImageJ with the Stackreg
plugin to account for nuclear migration in the recovery period. Regions of interest
encompassing the bleached area, the entire nuclei and a section of background were
selected and mean intensity values were quantiﬁed for each in ImageJ. These values
were then normalized and ﬁtted using the easyFRAP software52. All acquisitions
were performed on a Leica SP8 SMD X confocal microscope.
Initial rate values were calculated based on curve of best ﬁt generated in
MATLAB according to the following equation.
F xð Þ ¼ aexp bxð Þ þ cexp dxð Þ
Curves of best ﬁt were generated with the following coefﬁcient values (with 95%
conﬁdence bounds), mC2-f53BP1: a= 0.3191 (0.3083, 0.33), b= 0.0006296
(0.0005654, 0.0006938), c=−0.3105 (−0.32, −0.301), d=−0.009148 (−0.009856,
−0.00844), goodness of ﬁt, SSE= 0.00501, R-square= 0.9964, adjusted R-square
= 0.9963, RMSE= 0.006572; mC2-f53BP1ODm: a= 0.4695 (0.463, 0.4759), b=
0.000618 (0.0005858, 0.0006501), c=−0.5312 (−0.5555, −0.5069), d=−0.02533
(−0.02711, −0.02355), goodness of ﬁt, SSE= 0.01578, R-square= 0.9909, adjusted
R-square= 0.9906, RMSE= 0.01167; mC2-f53BP1LC8m: a= 0.4598 (0.4451,
0.4745), b= 0.0004644 (0.0004064, 0.0005225), c=−0.4654 (−0.4778, −0.4531),
d=−0.008194 (−0.008687, −0.007701), SSE= 0.00528, R-square= 0.9979,
adjusted R-square= 0.9979, RMSE= 0.006747. Rates for x= 10 s are presented
in Fig. 3e.
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Fig. 6 DYNLL1 and the OD mediate a bivalent mode of 53BP1
oligomerization. 53BP1 localisation and function is dependent upon bivalent
OD- and DYNLL1-mediated modes of oligomerization (top, left). OD-
mediated oligomerization alone is sufﬁcient for chromatin binding but
results in severe DSB repair defects (top, right). DYNLL1-mediated
oligomerization is also sufﬁcient to support recruitment of 53BP1 to damage
sites, but does not support DNA repair (bottom, left). Loss of both OD and
DYNLL1-mediated modes of oligomerization eliminates 53BP1 recruitment
to DNA damage sites and all associated repair functions (bottom, right)
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Expression and puriﬁcation of 53BP1. Smt3-His6-tagged fragments (amino acids
1131–1292) of wild type (LC8-OD), OD-mutated (ODm-LC8), LC8-mutated (OD-
LC8m), double mutant (LC8m-ODm) 53BP1, and DYNLL1 were expressed from
pET-17b in E. coli BL21(DE3). Cells were lysed by sonication in 20 mM HEPES pH
7.5, 250 mM NaCl, and 0.25 mM TCEP. Lysates were clariﬁed by centrifugation
and the supernatant was applied to a TALON IMAC column (Supplementary
Fig. 2a) or Ni-NTA agarose beads (Fig. 3f). Bound complexes were washed with
20 mM HEPES pH 7.5, 250 mM NaCl, 0.25 mM TCEP, supplemented with 10 mM
imidazole and then eluted by increasing the imidazole concentration to 250 mM.
Equal concentrations of eluate were then fractionated over a Superdex S200 col-
umn (Supplementary Fig. 2a).
In vivo tumourigenesis studies. All animal experiments were approved by the
Animal Ethics Committee of The Netherlands Cancer Institute (Amsterdam, the
Netherlands) and performed in accordance with the Dutch Act on Animal
Experimentation (November 2014). KB1P4 tumour organoids were established
previously and cultured in AdDMEM/F12 supplemented with 1M HEPES (Sigma),
GlutaMAX (Invitrogen), penicillin/streptomycin (Gibco), B27 (Gibco), 125 μM
N-acetyl-L-cysteine (Sigma), 50 ng/mL murine epidermal growth factor (Invitro-
gen) (Duarte et al.43). Tumour organoid transduction was performed by spino-
culation with pLentiCRISPRv2 lentiviral constructs in which either no gRNA or a
gRNA targeting ASCIZ was cloned. Following puromycin selection, modiﬁed
organoids were collected, incubated with TripLE at 37 °C for 5ʹ, dissociated into
single cells, washed in PBS, resuspended in tumour organoid medium and mixed in
a 1:1 ratio of tumour organoid suspension and BME in a cell concentration of
104 cells per 40 μl. Subsequently, 104 cells were transplanted in the fourth right
mammary fat pad of 6–9-week-old female NMRI nude mice. Mammary tumour
size was measured by caliper measurements and tumour volume was calculated
(0.5 × length × width2). Treatment of tumour bearing mice was initiated when
tumours reached a size of 50–100 mm3, at which point mice were stratiﬁed into the
untreated (n= 8) or olaparib treatment group (n= 8). Olaparib was administered
at 100 mg/kg intraperitoneally for 80 consecutive days. Animals were sacriﬁced
with CO2 when the tumour reached a volume of 1500 mm3. Sample sizes were not
pre-determined and no blinding or randomization was employed during analysis.
Quantiﬁcation and statistical analysis. Prism 6 (GraphPad Software Inc.) was
used for statistical analysis and production of all graphs and dot plots. The relevant
statistical methods and measures of signiﬁcance for each experiment are detailed in
the ﬁgure legends. Cell Proﬁler (Broad Institute) was used for automated quanti-
tation of immunoﬂuorescence data. Normalization of FRAP recovery curves was
performed using the easyFRAP software and curves of best ﬁt were generated in
MATLAB.
Data availability
The source data underlying Figs. 1d–f, 2b and d, 3b–d and f, 4d, f and g, 5a and b,
and Supplementary Figures 1c and d, 2b–e, 3a–d, 4b–f, 5c and e, and 6a and c are
provided as a Source Data ﬁle. All other original data and code that supports the
ﬁndings of this study are available from the corresponding author upon reasonable
request.
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